Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Biohaven Ltd.NYSE: BHVN
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $19.16M fell 7.9% year over year, ahead of the -13.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 32.2% from the prior quarter. Over 3 fiscal years it compounded at -16.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -7.9% holds above the trailing-twelve-month pace of -13.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 112.36M USD
- Year-over-year change
- +56.1%
- 4-year CAGR
- +14.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 112.36M | +56.1% |
| FY2024 | 2024-12-31 | 71.96M | +150.0% |
| FY2023 | 2023-12-31 | 28.79M | -85.1% |
| FY2022 | 2022-12-31 | 193.56M | +194.9% |
| FY2021 | 2021-12-31 | 65.64M | — |
Stock-Based Compensation vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -13.0% is the 10th highest of 11, against a peer median of +15.0%.
- Over three fiscal years its annual growth of -16.6% compares with a peer median of +42.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $145.91M USD | +2.8% | +19.1% | 220.8% | |
| LTM Jun 2026 | $85.94M USD | -13.0% | -16.6% | — | |
| LTM Jun 2026 | $49.78M USD | +71.5% | +62.2% | — | |
| LTM Sep 2026 | $48.87M USD | -15.9% | +4.1% | 72.0% | |
| LTM Sep 2026 | $37.41M USD | +60.8% | +68.9% | — | |
| LTM Sep 2026 | $36.81M USD | -0.7% | — | 32869.6% | |
| LTM Mar 2026 | $30.16M USD | +97.6% | +229.4% | — | |
| LTM Mar 2026 | $28.21M USD | +14.1% | — | 7.3% | |
| LTM Mar 2026 | $22.06M USD | +15.9% | +22.5% | 7.0% | |
| LTM Sep 2026 | €17.97M EUR | -7.1% | +18.8% | — | |
| LTM Mar 2026 | $16.53M USD | +220.6% | +92.7% | — | |
| Peer median (excluding BHVN) | — | +15.0% | +42.4% | 72.0% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 65.64M | 193.56M | 28.79M | 71.96M | 112.36M |
| Change in Working Capital | 1.66M | (28.6M) | 24.61M | 16.81M | 1.36M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.03M | 5.93M | 4.87M | 710K | (6.39M) |
| Other Working Capital | 639K | (34.53M) | 19.74M | 16.1M | 7.74M |
| Other Non-Cash Items | (740K) | 106.25M | 16.13M | 167.34M | 5.74M |
| Operating Cash Flow | (145.84M) | (297.69M) | (331.73M) | (582.45M) | (609.44M) |
| Capital Expenditures | (938K) | (41.07M) | (3.05M) | (4.05M) | (715K) |
| Acquisitions (Net) | 1.88M | 0 | 0 | 391K | 0 |
| Purchases of Investments | 0 | (263.72M) | (194.12M) | (745.68M) | (266.88M) |
| Sales of Investments | 0 | 0 | 327M | 504.36M | 570M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (1.85M) |
| Investing Cash Flow | 944K | (304.79M) | 129.83M | (244.97M) | 300.56M |
| Debt Repayment | 0 | 449.13M | 0 | 0 | 250M |
| Common Stock Issued | 0 | 283.8M | 243.23M | 675.52M | 189.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 138.45M | 34.66M | (31.32M) | 2.26M | (194K) |
| Financing Cash Flow | 138.45M | 767.6M | 211.91M | 677.77M | 439.12M |
| Effect of Forex Changes | 0 | 429K | (497K) | 75K | (3K) |
| Net Change in Cash | (6.45M) | 165.55M | 9.52M | (149.58M) | 130.24M |
| Free Cash Flow | (146.78M) | (338.76M) | (334.77M) | (586.5M) | (610.15M) |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.